男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Policies

Healthcare on the cusp of big leap

By LIU ZHIHUA | China Daily | Updated: 2020-12-07 07:39
Share
Share - WeChat
Staff members inspect equipment at a production workshop of Novo Nordisk (China) Pharmaceuticals on Feb 25. The parent company will invest $30.5 million to set up a new unit at the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone. [Photo/Xinhua]

China's economic resilience, policy supports, long-term strategy attract big-ticket investments

Tailwinds are not only offsetting the negative economic impact of COVID-19 on China's healthcare industry but also speeding up its evolution, heralding restructuring, expansion and rise in foreign investment flows, industry insiders said.

The glad tidings promise to make health one of society's top priorities as the nation swears by the new dual-circulation pattern for high-quality development in the post-pandemic era.

A confluence of several factors-growing demand for higher-quality healthcare, improved protection for intellectual property rights, deepening of China's reform and opening-up, reinforced commitment to globalization, a business-friendly environment, integration of cutting-edge technologies into the medical field, new agreements for regional trade and economic cooperation, and a long-term national health strategy-has created a near-perfect setting for the next big leap of the healthcare industry, they said.

To be sure, COVID-19 has caused massive job losses and a sharp fall in global foreign direct investment flows, but a quicker-than-expected economic recovery and remarkable resilience have made China one of the most attractive investment destinations in the global healthcare industry.

For instance, during the third China International Import Expo in early November in Shanghai, Novo Nordisk, a global healthcare leader in diabetes treatment, announced it will invest 200 million yuan ($30.5 million) to establish a new facility at the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone.

Novo Nordisk's new unit will foray into several market segments, including marketing, pharmaceutical research and development, and finished goods imports and distribution.

"The excellent business environment and preferential policy support in the Lingang Special Area will allow this new entity to become a powerful driver of Novo Nordisk's strategy of solidifying its value chain in China," the company said in a statement.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 松阳县| 商丘市| 灌阳县| 新巴尔虎左旗| 宁乡县| 乐安县| 台北县| 凤翔县| 明光市| 嫩江县| 桂林市| 天祝| 曲水县| 加查县| 得荣县| 金沙县| 武陟县| 达孜县| 诸城市| 上杭县| 陇南市| 通化县| 宁国市| 陆川县| 裕民县| 涡阳县| 定西市| 广州市| 铜川市| 景东| 赤峰市| 黄骅市| 平塘县| 涞水县| 资溪县| 九寨沟县| 扎囊县| 多伦县| 乐陵市| 潢川县| 肃南|